{"disease":{"id":"regorafenib","name":"regorafenib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05811481","title":"Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":192,"lead_sponsor_name":"WenBo Guo","has_results":false},{"nct_id":"NCT05794971","title":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05025592","title":"cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05426811","title":"Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"China Medical University, China","has_results":false},{"nct_id":"NCT05993702","title":"TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"China Medical University, China","has_results":false},{"nct_id":"NCT05048017","title":"Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07071961","title":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07343791","title":"Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":14,"lead_sponsor_name":"JIANG LONGWEI","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}